Accolade appointed Betsy Nabel and Jeff Brodsky as Board of Directors. Elizabeth ("Betsy") Nabel, M.D., is executive vice president for strategy at ModeX Therapeutics, developer of innovative immunotherapies for cancer and infectious diseases. Previously, Dr. Nabel served for eleven years as the president of Brigham and Women's Hospital, the second largest teaching hospital of Harvard Medical School and one of the largest hospitals in metro Boston. In his current role, Mr. Brodsky engages directly with management and the board on critical strategic issues related to executive talent, succession, and diversity and inclusion. He also helps lead the firm's COVID-19 response and brings direct experience in acquisition integration, most recently the acquisitions of E*TRADE and Eaton Vance. During more than 30 years at Morgan Stanley, Mr. Brodsky has held a variety of leadership roles across the human resources function, culminating in more than 10 years as the firm's chief human resources officer.
Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, womenâs health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.
ACCOLADE, INC. 
